Interestingly, in tumours predicted to be insensitive to CDK4/6i, transient administration of these drugs could be used to transiently arrest proliferation of normal cells and prevent chemotherapy‐induced myelosuppression, hence allowing to increase the dose of genotoxic drugs such as cisplatin and thus the therapeutic window between normal and transformed cells [115]. The gene discussed is CDK4; the disease is neoplasm.